Endocrine and bone
Somatostatin analogues
Long-acting versions of somatostatin that suppress growth hormone, gut hormones and splanchnic blood flow: used in acromegaly from pituitary adenomas, neuroendocrine tumours and bleeding oesophageal varices.
Mechanism of action
- Somatostatin inhibits the release of growth hormone, TSH, insulin, glucagon and many gut hormones through somatostatin receptors (mainly SSTR2 and SSTR5).
- Octreotide and lanreotide act on the same receptors but last much longer.
- They reduce growth hormone and IGF-1 in acromegaly and can shrink somatotroph adenomas.
- They constrict splanchnic vessels, lowering portal pressure in variceal bleeding.
Molecular targets
- Somatostatin receptors (SSTR2, SSTR5): Agonist
Drugs in Somatostatin analogues
- Octreotide (Subcutaneous, intravenous or monthly depot.)
- Lanreotide (Depot injection.)
- Pasireotide (Broader receptor profile; Cushing disease.)
Therapeutic uses
- Acromegaly from growth hormone-secreting pituitary adenomas
- Acute variceal bleeding in cirrhosis
- Symptoms of carcinoid and other neuroendocrine tumours
Diseases it treats
Adverse effects
- Abdominal cramps, nausea and diarrhoea
- Gallstones and biliary sludge, from reduced gallbladder contraction
- Hyperglycaemia or hypoglycaemia
- Bradycardia
Contraindications by condition
- Gallstones and cholecystitis (Use with care): Reduced gallbladder emptying favours new stones and sludge.
- Diabetes (Use with care): They alter insulin and glucagon secretion.
Connected topics
Written from
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 23, Pituitary and Thyroid, Somatostatin
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 37, Hypothalamic & Pituitary Hormones, Somatostatin analogs
Educational reference. Not medical advice, diagnosis or treatment.